Comparative Pharmacology
Head-to-head clinical analysis: CABOMETYX versus JASCAYD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABOMETYX versus JASCAYD.
CABOMETYX vs JASCAYD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cabozantinib is a small molecule inhibitor of multiple receptor tyrosine kinases, including MET, VEGFR2, RET, AXL, KIT, and FLT3. It inhibits tumor growth, angiogenesis, and metastasis by blocking these pathways.
JASCAYD (tasquinimod) is a selective allosteric inhibitor of S100A9, which binds to toll-like receptor 4 (TLR4) and receptor for advanced glycation end-products (RAGE). It modulates the tumor microenvironment by inhibiting myeloid-derived suppressor cell (MDSC) recruitment and function, reducing angiogenesis, and enhancing anti-tumor immune responses.
60 mg orally once daily for the first 21 days of a 21-day cycle, with or without food, for renal cell carcinoma; for hepatocellular carcinoma, 60 mg orally once daily.
Adults: 300 mg orally twice daily with food.
None Documented
None Documented
Terminal half-life approximately 99 hours (range 80–120 h). Supports once-daily dosing with steady-state achieved within 15 days.
Terminal elimination half-life is 12-15 hours; clinically relevant for once-daily dosing.
Primarily fecal (54%) with minimal renal excretion (27% unchanged drug; <10% as metabolites). Biliary excretion contributes to fecal elimination.
Primarily renal excretion (80%) as unchanged drug; 20% fecal via biliary elimination.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor